(Corrects size of drop in lead, second paragraph.)
Dec. 6 (Bloomberg) -- Protalix BioTherapeutics Inc. fell the most in more than nine months after the biotechnology company said the U.S. Food and Drug Administration delayed a decision on its Gaucher disease protein.
The shares tumbled 21 percent, the most since Feb. 27, to 18.30 shekels at 3:43 p.m. in Tel Aviv.
Global market map: MMAP <GO> Most active stocks: MOST <GO> Global stocks stories: TOP STK <GO> Most read stock market stories: MNI STK <GO> Israel Daybook: NI ISRAELDAY <GO> Top Israel stories: TOP ISRAEL <GO>
--Editors: Claudia Maedler, Shaji Mathew
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org